Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bortezomib + cyclophosphamide + thalidomide + dexamethasone
- Development stage
- Phase 2
- Lead developer
- Grupo de Estudos Multicêntricos em Onco-Hematologia
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
bortezomib + cyclophosphamide + thalidomide + dexamethasone refers to the collective set of therapeutic agents utilized in a Phase 3 clinical trial (NCT01002183) conducted by the Grupo de Estudos Multicentricos em Onco-Hematologia (GEMOH). This multicenter Brazilian study compared two distinct triple-drug induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: VCD (comprising bortezomib, cyclophosphamide, and dexamethasone) and CTD (comprising cyclophosphamide, thalidomide, and dexamethasone). Bortezomib acts as a proteasome inhibitor, cyclophosphamide as an alkylating agent, thalidomide as an immunomodulatory drug targeting cereblon, and dexamethasone as a corticosteroid. The trial aimed to determine the superior induction protocol, ultimately finding that the bortezomib-containing VCD regimen achieved significantly higher response rates than the thalidomide-containing CTD regimen.
- Other names
- VCD vs CTD GEMOH trial regimen
02
Targets
PSMB5 (Proteasome subunit beta Type-5)CRBN (Cereblon)N7-G (DNA guanine-N7 adduct)GR (Glucocorticoid receptor)DNA
Beyond the preview
Go deeper on bortezomib + cyclophosphamide + thalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bortezomib + cyclophosphamide + thalidomide + dexamethasone.